Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hangzhou Tigermed Consulting CoFRA:5HZ1 -1.96%87 ROC (Joel Greenblatt) % is 48.00% as of Mar. 2026, which is 68% below its 10-year median of 150.81. GuruFocus rates FRA:5HZ1 with a GF Score™ of 87/100 and a GF Value™ of €4.91 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks better than 91.47% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Hangzhou Tigermed Consulting Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 48.00%.
The historical rank and industry rank for Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:5HZ1'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.16 Med: 150.81 Max: 410.78
Current: 66.13
During the past 13 years, Hangzhou Tigermed Consulting Co's highest ROC (Joel Greenblatt) % was 410.78%. The lowest was 43.16%. And the median was 150.81%.
FRA:5HZ1's ROC (Joel Greenblatt) % is ranked better than 91.47% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.61
vs FRA:5HZ1: 66.13
Hangzhou Tigermed Consulting Co (FRA:5HZ1) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co ROC (Joel Greenblatt) % Chart
FRA:5HZ1 vs TMO, DHR, IDXX: ROC (Joel Greenblatt) % Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co ROC (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) % falls into.
Hangzhou Tigermed Consulting Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 48.00% mean?
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a ROC (Joel Greenblatt) % of 48.00% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is 68% below median its historical median of 150.81. Over the past decade, Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) % has ranged from 43.16 to 410.78. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #18 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 8.5%.
Is Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) % too high?
Hangzhou Tigermed Consulting Co's current ROC (Joel Greenblatt) % of 48.00% is 68% below median its 10-year median of 150.81. Over the past 10 years, this metric has ranged from a low of 43.16 to a high of 410.78. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #18 out of 211 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's ROC (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #18 out of 211 companies for ROC (Joel Greenblatt) %. This places Hangzhou Tigermed Consulting Co in the top 9% of its industry — outperforming the majority of peers. Historically, Hangzhou Tigermed Consulting Co's own ROC (Joel Greenblatt) % has ranged from 43.16 to 410.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good ROC (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Hangzhou Tigermed Consulting Co and its competitors. Hangzhou Tigermed Consulting Co's current ROC (Joel Greenblatt) % is 48.00%, which is 68% below median its own 10-year median of 150.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €4.91, compared to a current price of €4.00 — trading 18.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is 48.00%, which is 68% below median its 10-year median of 150.81. Hangzhou Tigermed Consulting Co's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current ROC (Joel Greenblatt) % is 48.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €4.00 is trading 18.5% below its estimated GF Value™ of €4.91.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for FRA:5HZ1:
ROC (Joel Greenblatt) %: 48.00% (68% below median its 10-year median of 150.81)
GF Value™: €4.91 vs. price of €4.00 (18.5% below fair value)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
87GF Score
Get the complete analysis for FRA:5HZ1
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
